NCI-2020-11363

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)

This is a Phase II, multicenter, open-label study called DESTINY-PanTumor02, testing the effectiveness and safety of Trastuzumab Deruxtecan (T-DXd or DS-8201a) for treating tumors that express the HER2 protein. HER2 is a protein on the surface of some cancer cells that can cause them to grow and divide more quickly when present in high amounts. The drug combines trastuzumab, an antibody that targets HER2 to stop cancer cells from growing, with deruxtecan, a chemotherapy drug that delivers powerful treatment directly to HER2-positive cancer cells. The goal of the study is to see how well this drug works and how safe it is for treating HER2-positive cancers.

Phase II: An advanced point of testing, where they're trying to confirm if a treatment works well.

Open Label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04482309

Clinical Trial Site: Sinai

To see all available clinical trials click here.